Defence Therapeutics successfully develops ACCUMTM -mRNA cancer vaccine
Canadian biopharmaceutical pioneer Defence Therapeutics has revealed it has successfully conjugated mRNA molecules to AccumTM – a significant breakthrough that looks to enhance the...
Defence to perform final AccuTOXTM preclinical study before Phase I cancer trial
Defence Therapeutics has announced it is performing a final preclinical study to validate the efficacy of AccuTOXTM combined with immune-checkpoint inhibitors before initiating a...
Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates
Defence Therapeutics Inc. is pleased to announce that they have signed a collaboration agreement with Orano to develop next-generation radio-immuno-conjugates using their intracellular targeting...
B Medical Systems donates transport boxes to Turkey and Syria
To support the relief effort in Turkey and Syria following February's earthquakes, B Medical Systems has donated 50 medical transport boxes.
B Medical Systems collaborated...
Defence advances to phase I clinical trials of the Accum technology
Defence Therapeutics Inc. is pleased to update its stakeholders on its completed achievements and outline the future milestones for AccumTM set for 2023.
Over the...
B Medical Systems’ cold chain transport box receives CERTICOL label
The CERTICOLD quality label guarantees B Medical Systems’ cold chain transport boxes RCW25 are conforming to European GDP guidelines.
B Medical Systems, a global leader...
Defence work with City of Hope in filing a new AccuTOX cancer programme
Defence Therapeutics has teamed up with City of Hope to submit an application for the clinical trialling of their AccuTOX TM technology.
The Canadian biopharmaceutical...
Defence Therapeutics begins manufacturing of it’s ARM vaccine
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the start...
Defence Therapeutics begin toxicology study on intranasal AccutoxTM
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start...
Defence Therapeutics has melanoma vaccine validated
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation...
Defence Therapeutics has US patent accepted for Accum
Defence Therapeutics Inc, a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate...
Defence Therapeutics launch Accum-mRNA vaccine programme
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement...
Defence’s novel Accutox intranasal reduces 50% of cancer nodules
Defence Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, has just completed a pre-clinical study using...
Defence Therapeutics are using Accum technology in mRNA vaccines
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its...
How dangerous is mould in the home?
Amid the rise of mould-related health incidents in the UK, Gama Healthcare investigates what can be done to combat the risk of mould in...
Adopt point-of-care diagnostics to cut carbon emissions, say over 80% of GPs
A new study by LumiraDX has found that the majority of the GP workforce believes that point-of-care diagnostics could cut carbon emissions.
Point-of-care diagnostics must...
Defence Therapeutics to begin phase 1 trial for new anti-cancer treatment
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful...
Defence’s successful study on the ACCUVAC-PT007 vaccine
Defence Therapeutics Inc. has announced its successful study on its ACCUVAC-PT007 vaccine, which targets cervical cancer.
Defence Therapeutics Inc. a Canadian biopharmaceutical company specialised in...
LumiraDx continue rapid microfluidic immunoassay HbA1c test expansion
LumiraDx's rapid microfluidic immunoassay HbA1c test will now be available in Europe, parts of the Middle East, Asia, Latin America, and Africa.
Early customers...
Luxembourg government approve Azenta MoU on cold chain solutions
Azenta, Inc. and the Government of Luxembourg today announced the signing of a Memorandum of Understanding (MoU) to facilitate continued healthcare technology and the...